Brainstorm Cell Therapeutics Stock Current Valuation
| GHDN Stock | EUR 2.69 0.00 0.00% |
Valuation analysis of Brainstorm Cell Ther helps investors to measure Brainstorm Cell's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Brainstorm Cell's price fluctuation is risky at this time. Calculation of the real value of Brainstorm Cell Ther is based on 3 months time horizon. Increasing Brainstorm Cell's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Brainstorm stock is determined by what a typical buyer is willing to pay for full or partial control of Brainstorm Cell Therapeutics. Since Brainstorm Cell is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Brainstorm Stock. However, Brainstorm Cell's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.69 | Real 2.47 | Hype 2.69 | Naive 2.82 |
The real value of Brainstorm Stock, also known as its intrinsic value, is the underlying worth of Brainstorm Cell Ther Company, which is reflected in its stock price. It is based on Brainstorm Cell's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Brainstorm Cell's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Brainstorm Cell Therapeutics helps investors to forecast how Brainstorm stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Brainstorm Cell more accurately as focusing exclusively on Brainstorm Cell's fundamentals will not take into account other important factors: Brainstorm Cell Therapeutics Company Current Valuation Analysis
Brainstorm Cell's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Brainstorm Cell Current Valuation | 44.56 M |
Most of Brainstorm Cell's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Brainstorm Cell Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Brainstorm Cell Therapeutics has a Current Valuation of 44.56 M. This is 99.69% lower than that of the Healthcare sector and 99.04% lower than that of the Biotechnology industry. The current valuation for all Germany stocks is 99.73% higher than that of the company.
Brainstorm Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Brainstorm Cell's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Brainstorm Cell could also be used in its relative valuation, which is a method of valuing Brainstorm Cell by comparing valuation metrics of similar companies.Brainstorm Cell is currently under evaluation in current valuation category among its peers.
Brainstorm Fundamentals
| Return On Equity | -1.93 | |||
| Return On Asset | -0.68 | |||
| Current Valuation | 44.56 M | |||
| Shares Outstanding | 36.54 M | |||
| Shares Owned By Insiders | 22.70 % | |||
| Shares Owned By Institutions | 10.41 % | |||
| Price To Book | 36.30 X | |||
| EBITDA | (24.28 M) | |||
| Net Income | (24.46 M) | |||
| Cash And Equivalents | 6.22 M | |||
| Cash Per Share | 0.29 X | |||
| Total Debt | 3.04 M | |||
| Debt To Equity | 934.00 % | |||
| Current Ratio | 0.97 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (26.27 M) | |||
| Earnings Per Share | (0.68) X | |||
| Target Price | 11.5 | |||
| Number Of Employees | 43 | |||
| Beta | -0.36 | |||
| Market Capitalization | 74.73 M | |||
| Total Asset | 29.28 M | |||
| Z Score | 14.4 | |||
| Net Asset | 29.28 M |
About Brainstorm Cell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Brainstorm Cell Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brainstorm Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brainstorm Cell Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Brainstorm Stock
When determining whether Brainstorm Cell Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Brainstorm Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainstorm Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainstorm Cell Therapeutics Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Brainstorm Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.